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Generic residue numbers facilitate comparisons of, for
example, mutational effects, ligand interactions, and
structural motifs. The numbering scheme by Ballesteros
and Weinstein for residues within the class A GPCRs (G
protein-coupled receptors) has more than 1100 citations,
and the recent crystal structures for classes B, C, and F
now call for a community consensus in residue number-
ing within and across these classes. Furthermore, the
structural era has uncovered helix bulges and constric-
tions that offset the generic residue numbers. The use of
generic residue numbers depends on convenient access
by pharmacologists, chemists, and structural biologists.
We review the generic residue numbering schemes for
each GPCR class, as well as a complementary structure-
based scheme, and provide illustrative examples and
GPCR database (GPCRDB) web tools to number any
receptor sequence or structure.
New era in GPCR research
G protein-coupled receptors (GPCRs) constitute the largest
family of human cell surface receptors [1]. They respond
endogenously to ions, neurotransmitters, lipids, carbohy-
drates, nucleotides, amino acids, peptides and proteins; and
also sense light, pain, tastes, and odors [2]. Their abundance
in human physiological systems, as well as their accessibili-
ty and druggability, have made them a major drug target
family – 30% of the marketed drugs act on GPCRs [3]. The
GPCRs are typically classified into the classes A–F [4], or
according to the alternative GRAFS (glutamate, rhodopsin,
adhesion, frizzled/taste2, secretin) system for the human
receptors [5] (Table 1). In recent years, the number of GPCR
crystal structures has grown exponentially and are now
available for all of the human classes (A–C, F), except the
Taste type 2 receptors. These structures have revealed
common conformational changes during receptor activation,
allosteric modulation by ions, lipids, cholesterol, and water;
as well as interactions with the G protein [6–8].
Generic residue numbers - maps to navigate GPCR
topology
All GPCRs share a structural core of seven transmembrane
(7TM) helices, making up the machinery for signal trans-
duction across the cell membrane. The 7TM domain con-
tains or is part of the binding site of class A and B1 receptor
ligands, and serves as a site for allosteric modulation of class
B2, C, and F GPCRs [9,10]. So far, 109 GPCRs have been
drugged [11], the vast majority with ligands binding within
the TM region [12]. The conserved 7TM scaffold allows for
the alignment of sequences or structures to identify the
corresponding residues, which are indexed with a generic
residue number. Such generic residue numbers allow for
comparison of, for example, mutant effects, ligand interac-
tions, and structural features across receptor subtypes,
species orthologs, or receptor subfamilies. For example, such
residue numbers have been used to define the shared
ligand-accessible residue positions within the TM bundle
[13]. These conserved positions are common placeholders,
while receptor sequences vary and so compose the unique
mosaic responsible for ligand affinity and selectivity.
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Class A GPCR residue numbering
The Ballesteros–Weinstein numbering scheme [14] is
based on the presence of highly conserved residues in each
of the seven transmembrane (TM) helices. It consists of two
numbers where the first denotes the helix, 1–7, and the
second the residue position relative to the most-conserved
residue, defined as number 50. For example, 5.42 denotes a
residue located in TM5, eight residues before the most-
conserved residue, P5.50. The residue numbers can be
counted directly within the receptor protein sequence
(alignment); however, the reference residues are not con-
served in all receptors and the numbering is therefore not
always straightforward (class A conservation: N1.50: 98%,
D2.50: 90%, R3.50: 95%, W4.50: 97%, P5.50: 78%, P6.50:
99%, P7.50: 88% [15]).
Alternative class A numbering schemes have been pre-
sented by Oliveira [16], Baldwin [17,18], and Schwartz
[19,20]. They have a common basis in enumerating residue
positions from the helix extracellular ends, aiming to assign
residues located at the same depth in the membrane with
the same numbers, for example 3.16 and 6.16 (this reverses
the TM2, TM4, and TM6 sequences). However, none of the
schemes, which use different starting points and numbers,
succeeds because GPCR crystal structures have uncovered
extensive variations in the length and inclination of TM
helices. The alternative schemes differ in format: Oliveira
numbers (the oldest numbering scheme) omit the dot sepa-
rator to make the numbers computationally more accessi-
ble, and Baldwin and Schwartz helix numbers are denoted
with roman numerals, I–VII.
Class B, C, and F GPCR residue numbering
Class B, C, and F schemes have been established using the
same procedure as the class A Ballesteros-Weinstein sys-
tem, but use unique reference positions (X.50) such that
the residue numbers can be counted directly within the
receptor protein sequence (alignment). The class B GPCR
Wootten [21] scheme is based on the B1/secretin subclass,
but the reference residues are the most conserved also for
five of the B2/adhesion receptor helices and the remaining
two, TM3–4, still display high conservation (E3.50 58% and
W4.50 42%) [15]. This scheme was used in the publications
of the crystal structures of both the glucagon receptor
[22] and corticotropin-releasing factor receptor 1 (CRF1)
[23]. The class C GPCR Pin [24] numbering was used in
the publication of the metabotropic glutamate receptor 5
(mGlu5) crystal structure [25]. The class F GPCR Wang
scheme was introduced in the recent publication of Smooth-
ened (SMO) crystal structures [26]. In humans, this is a
small class with only 11 members and, in cases where a helix
has more than one fully conserved position, the one struc-
turally closest to the class A Ballesteros-Weinstein was used
as the reference position. Because all schemes use identical
formatting, it has been suggested to append the class name
(A–F) where clarification is needed, for example, 3.50b for
class B Wootten numbers [27].
Cross-class GPCR residue numbering
The low sequence conservation between the GPCR classes
has hitherto hindered (correct) sequence alignments, al-
though some inter-class receptor modeling studies correct-
ly aligned the majority of the seven helices (e.g., [28–30]).
The structural conservation is higher and the recent crys-
tallographic data have opened up for structure-based se-
quence alignments from class A to B [22,23,27], C [25,31],
and F [32,33]. Some helices display large inter-class lateral
deviations or different bending but, because adjacent heli-
ces are often translated in the same direction, structural
multi-residue motifs with a shared functional mechanism
are often conserved across the classes. The published cross-
class residue comparisons have utilized the Ballesteros-
Weinstein numbers, and where necessary included a class-
specific number, for example Y7.53a.57b. Furthermore,
reference cross-class alignments, based on the available
crystal structures, are available in GPCRDB (http://www.
gpcrdb.org; see below). Table 2 shows the alignment of the
class specific Ballesteros-Weinstein numbers based on
structural alignment of crystal structures of representa-
tive receptors from class A (bRho), B (Glucagon receptor), C
(mGlu1), and F (SMO).
Example 1: class A/B common receptor activation motif
in TM7
A Tyr residue Y7.53a.57b, conserved in both class A (Y7.53)
and class B (Y7.57) GPCRs, has been proposed to play an
important role in the activation of both receptor families
(Figure 1) [34]. In the Glucagon receptor (class B GPCR)
crystal structure [22] Y4007.57b forms hydrogen bonds with
Table 1. Human GPCR classification and crystal structuresa
Class [1] GRAFS [2]
Family
Note # Human
receptors [3]
Crystal Structures (7TM domain)
A Rhodopsin Includes 400 olfactory
receptors [4]
282 (+ 400 olfactory) 2000: rhodopsin [5], 2007: b2-adrenoceptor;
and today: 23 receptors in total [6]
B Secretin Also referred to as B1 15 2013: Corticotropin-releasing factor receptor
1 [7] and Glucagon receptor [8]
Adhesion Also referred to as B2 33 
C Glutamate Includes Taste type
1 receptors
22 2014: Metabotropic glutamate receptor 1 [76]
and 5 [77]
F Frizzled 11 2013: Smoothened [78]
O (Other) Taste2 Re-classified as own
family [79], although
originally grouped
with Frizzled [2]
24 
aClasses D and E do not exist in human, and are fungal mating pheromone receptors and cAMP receptors, respectively.
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the conserved T3516.42b and E2453.50b residues [27] in a
conformation that in class A GPCRs is linked to activation
and interaction with the G protein [6,35]. In CRF1, the
thermostabilizing mutation Y3637.57bA contributes to the
shift in the conformation of the receptor towards an inactive
state [23].
Example 2: class A/C unique features of conserved
residues in TM6 involved in ligand binding and receptor
activation
In both classes A and C, TM6 contains a highly conserved
tryptophan at position 6.48a.50c. This residue occupies an
equivalent position in both classes, but in the structures of
the metabotropic glutamate receptors mGlu1 [31] and
mGlu5 [25] TM6 has moved laterally away from TM7
compared to class A. In contrast with class A, this move-
ment allows W6.50c to create a hydrogen bond to the back-
bone carbonyl of 5.44c, bridging TM6 to TM5. Despite this
conformational difference, the aromatic residues W6.48a.50c
and F6.51a.53c play a role in the ligand binding in both
classes (allosteric ligands for class C), as shown in the
class A [6,8] and C [25,31] crystal structures (Figure 2).
Their role in ligand binding and potentially in receptor
activation is supported by mutation studies for several
class A aminergic [36,37], chemokine [38], adenosine
[39], and lipid [40] receptors, as well as class C receptors
mGlu1 [41], mGlu5 [42,43], and CASR (calcium-sensing
receptor) [44,45].
Example 3: class A/B/C/F common hydrophobic core
In the helical bundle, TM3 represents a structural and
functional hub [6] being centrally placed with contacts to
all other helices except TM1. TM3 plays a central role in
activation [6], which involves the upward movement of
TM3 along its axis and a rotation of TM6 [7]. Comparisons
of inactive and activated class A receptor structures have
led to the proposal of a hydrophobic mechanism hindering
activation that consists of the rearrangement of a core of
highly conserved hydrophobic residues in 3.43a together
with V/I/L6.40a, V/I/L6.41a, and F6.44a [7]. This core is
well conserved in all human GPCRs: all classes A, B, C, and
T3516.42b
Y3267.53a
Y4007.57b
E2453.50b
Y3637.57b A
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Figure 1. Class A/B common receptor-activation motif in transmembrane (TM) helix
TM7. Intracellular view of structural superposition of conrticotropin-releasing factor
receptor 1 (CRF1) (magenta, PDB: 4K5Y), the glucagon receptor (cyan, PDB: 4L6R),
and the b2-adrenoceptor (yellow, PDB: 3SN6). The conserved Tyr residue Y
7.53a.57b
and in CRF1 the thermostabilizing mutation Y363
7.57bA are shown in stick
representation. In the glucagon receptor the polar interactions of Y4007.57b with
T3516.42b and E2453.50b residues are represented as broken lines.
Table 2. Alignment of the class-specific generic residue
numbers based on structural alignment of crystal structures
of representative receptors from class A (bovine rhodopsin,
bRho), B (glucagon receptor), C (metabotropic glutamate
receptor 1, mGlu1), and F (Smoothene, SMO). Class-specific
reference residue positions (X.50) for each of the seven TM
helices are given in bold font.
Helix Class A
(bRho)
Class B
(GCGR)
Class C
(mGluR1)
Class F
(SMO)
TM1 G511.46a S1521.50b G6031.50c T2411.43f
N551.50a L1561.54b T6071.54c T2451.47f
T581.53a A1591.57b V6101.57b T2481.50f
TM2 L762.43a H1772.50b C6311.39c L2672.42f
D832.50a F1842.57b I6381.46c F2742.47f
L842.51a V1852.58b F6391.47c F2752.50f
F882.55a S1892.62b Y6422.50c S2782.53f
TM3 L1313.46a E2453.50b K6783.50c A3273.46f
R1353.50a L2493.54b I3543.54c W3313.50f
TM4 W1614.50a W2724.50b I7144.40c W3654.50f
P1714.60a W2824.60b L7244.50c I3754.60f
TM5 V2115.45x46a P3105.42 Y7595.46c P4075.50f
P2155.50a A3145.46b L7635.50c V4115.54f
I2195.54a N3185.50b C7673.54c G4155.58f
TM6 L2626.45a G3596.50b C7956.47c L4645.45f
W2656.48a E3626.53b W7986.50c F4675.47f
P2676.50a V3646.55b A8006.52c C4695.49f
Y2686.51a F3656.56b F8016.53c H4705.50f
TM7 A2997.46a G3937.50b V8237.40c F5267.46f
P3037.50a A3977.54 L8277.44c I5307.50f
  P8337.50c V5367.56f
L7575.44c
W2656.48a
Y2686.51a
F8016.53c
11-cis-renal
FITM
W7986.50c
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Figure 2. Class A/C unique features of conserved residues in TM6 involved in ligand
binding and receptor activation. Side view of rhodopsin (purple, PDB: 2X72) and the
metabotropic glutamate receptor mGlu1 (green, PDB: 4OR2). 11-cis-retinal and FITM
are shown in line representation. L5.44c and the aromatic residues W6.48a.50c and Y/
F6.51a.53c are shown in stick representation. In mGlu1 the polar interaction between
W6.50c and L5.44c is represented as a broken line. Abbreviation: FITM, 4-fluoro-N-[4-[6-
(isopropylamino)pyrimidin-4-yl]-1,3-thiazol-2-yl]-N-methylbenzamide.
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F have a highly conserved hydrophobic residue in position
3.43a.47b.47c.43f (mainly L, M, L, and W; respectively)
that forms contacts with at least two hydrophobic residues
in the equivalent TM6 positions 6.40a.45b.42c.39f,
6.41a.46b.43c.40f, and 6.44a.49b.46c.43f (recently de-
scribed in Bortolato et al.) [15,33]. Furthermore, in all
classes except C the other side of TM3 has hydrophobic
contact with a highly conserved W4.50abf (same index in
all classes) on TM4 [15,33].
Extracellular loop 2 residue numbering
Sequence analysis shows that there is a large diversity in
the lengths and compositions of the N- and C-termini as
well as in the extracellular and intracellular loops con-
necting the TM helices of GPCRs [46]. Nevertheless, for
the extracellular loop 2 (EL2) a similar residue-number-
ing scheme has been applied [41,47] in which EL2 resi-
dues are labeled 45.X, indicating the location between
TM4 and TM5 (‘‘45’’) [47]. The reference position (X.50) is
a conserved cysteine forming a disulfide bridge with a
TM3 residue C3.25a.29b.29c.25f, which is fully (100%)
conserved in the classes B, C, and F, and 88% conserved
in class A [15,47]. The second extracellular loops of many
GPCRs have approximately the same number of residues
upstream and downstream of C45.50 [47]. However, the
loop regions of GPCRs are structurally less conserved
than the TM helices [6], and EL2 is no exception. Thus,
in comparisons across receptor subfamilies the structur-
al conservation is limited to the backbone of 45.50–45.52.
This short stretch is still of high importance because the
45.52 sidechain is often directed into the 7TM binding
pocket [47]. Longer loop modeling has to be reserved to
receptors where there is a template with the same length
in TM4–C45.50 and C45.50–TM5, respectively, and guid-
ed by experimental restraints. Moreover, although re-
cent GPCR Dock challenges show that although the
positions of specific EL2 residues close to C45.50 can
be correctly predicted, computational modeling of
complete EL2 structures is still highly challenging
[48–50].
Mind the gap – introducing a novel complementary
crystal structure-based GPCR residue numbering
Class A GPCRs have long been known to contain helix
kinks in TM5–7 that are induced by highly conserved
proline residues, which are unable to form backbone
hydrogen bonds [51]. Upon receptor activation, they
act as hinges that allow the helices to tilt inwards to
tighten the ligand cavity and outwards to widen the G
protein-binding pocket [7]. This does not affect the ge-
neric residue numbers because the best corresponding
alignment of residues is obtained knowing that receptor
structures are dynamic and the same helix in two recep-
tors can in most cases tilt to adopt a similar position.
Consequently, the GPCR 7TM was assumed to be uni-
formly shaped, leading to the long-standing principle to
never insert gaps within sequence alignments of the TM
helices.
As we entered the structural era, we discovered that the
GPCR 7TM frequently contains distortions of another type:
bulges and constrictions that are local to one helix turn, but
offset the generic numbers of all following residues in the
helix. This is because there is one additional residue in a
bulged (p-helical), and one absent residue in a constricted
(310-helical) helical turn, respectively. This causes a single
unmatched position, in other words a gap in structure and
sequence compared to the corresponding undistorted helix.
To date, more than 110 crystal structures of 27 unique
GPCRs, have uncovered nine bulges (Figures 3A–I) and six
constrictions (Figures 3J–O) in TM1, TM2, TM4, TM5,
TM6, and TM7 [52]. These range all classes A, B, C and
F; and two constrictions are shared by two classes
(Figures 3N–O). Some helical distortions affect only a
specific receptor subtype (Figure 3J), whereas others are
shared by the majority (Figures 3E, H, and O) or all
(Figures 3I and O) members of a GPCR class. Of note,
the highly conserved proline residues P6.50x50 and
P7.50x50 are associated with kinks in all available class
A GPCR structures, but entail only few (12%, Figure 3F) or
no observed bulges, respectively, in other words, they lack
the backbone hydrogen bond but have no amino acid
insertion.
GPCRDB has implemented a complementary structure-
based scheme that corrects for bulges and constrictions.
The scheme is based on pairwise superposition of inactive
receptor structures using the ‘WHAT IF’ program
[53]. Each helix is analyzed separately, and a bulge or
constriction is defined by comparison to an undistorted
reference. The single bulge residue that protrudes the
furthest (Figures 3A–I) is assigned the same number as
the preceding residue followed by a 1, for example, a bulge
after residue 46 is given the number 461. The position
lacking in a constriction (Figures 3J–O) is simply skipped
in the residue numbering. Uncertain cases are put on a
‘waiting’ list of potential bulges/constrictions that require
additional crystallographic evidence. GPCRDB numbers
are assigned to all distortions, even those that seem to be
shared by all members of a GPCR class. This is for two
reasons. First, it allows cross-class structure/sequence
alignments, and second, it future-proofs the residue num-
bers by avoiding updates should another class-member
with an undistorted helix be crystallized.
To distinguish the GPCRDB scheme, it uses a unique
separator x (e.g., 5x46) to denote that it is based on
experimental structures, which are predominantly X-ray
structures although NMR structures are also taken into
account when available. For clarity, it is recommended to
use the combination of the sequence- and structure-based
numbers, for example 2.58x57, unless the comparison only
includes crystallized receptors.
Example 4: TM2 bulge affects chemokine and opioid
receptor binding site residues
Although most GPCR crystal structures contain an alpha
bulge in TM2 [52] at position 2.55x551, chemokine recep-
tors and opioid receptors contain a S/T2.56XP2.58 sequence
motif that stabilizes a different helical conformation. Site-
directed mutagenesis data probing the TM2–TM3 inter-
face [54] and receptor–ligand interactions in chemokine
receptors [38,55] were used to successfully predict the TM2
conformation of CXCR4 (chemokine (C–X–C motif) recep-
tor 4) and interactions between W942.60 and D972.63 and
Review Trends in Pharmacological Sciences January 2015, Vol. 36, No. 1
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(A) (B) (C) (D)
(E)
(I) (J) (K)
(F) (G) (H)
(L) (M)
Bulges
Constricons
(N) (O)
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Figure 3. Bulges and constrictions in GPCR class A, B, C and F crystal structures. Bulged (A–I) and constricted (J–O) helical turns have one additional and lacking residue
position, respectively, when superposed to an undistorted helix reference. The structural and sequence alignments of equivalent residues therefor contain a gap, which
offsets all following generic residue numbers (gray). The GPCRDB generic residue numbers (black) are structure-based and account for bulges and constrictions by
numbering an extra residue as the preceding followed by a 1, for example 1.40x411, and by skipping a lacking position. To facilitate cross-class comparisons, their
alignments have been assigned GPCRDB numbers for all classes. The percentages to the lower right of the structures represent the conservation/frequency of the bulge or
(Figure legend continued on the bottom of the next page.)
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the co-crystallized 1T1t ligand prior to the CXCR4–1T1t
crystal structure [56] in the GPCR Dock 2010 challenge
[49,57] (Figure 4A). CXCR4 models based on an ungapped
sequence alignment between CXCR4 and the crystal struc-
ture templates available at the time of this GPCR modeling
competition (rhodopsin, adrenoceptors b1 and b2, and the
adenosine receptor A2AR) incorrectly oriented W94
2.60 and
D972.63 towards the membrane layer instead of towards
the ligand-binding site [49,57]. Residues at positions
2.60 and 2.63 interact with co-crystallized ligands in
CCR5 (chemokine C–C motif receptor) (W2.60, Y2.63), the
k receptor (kappa 1 opioid receptor) (Q1152.60, V1182.63)
[58], and NOP receptor (opiate receptor like-1 receptor)
(Q1072.60, D1102.63) [59] crystal structures. Moreover, mu-
tagenesis studies indicate that 2.63 (K108 and N129,
respectively) plays a role in the ligand selectivity of d
and m opioid receptors [55,60]. These residues structurally
align with residues L1012.64x63 and H932.64x63 in adreno-
ceptors b1 (Figure 4B) and b2, respectively, two examples of
GPCRs that contain a bulge in TM2. L1012.64x63 interacts
with carmeterol, dobutamine, and carvedilol (Figure 4B) in
b1-adrenoceptor crystal structures[61,62], while BI-
167107 interacts with H932.64x63, and FAUC50 covalently
binds the H932.64x63C cysteine mutant in b2-adrenoceptor
crystal structures [35,63].
Example 5: TM4 constriction affects the alignment of
aminergic receptor binding site residues
The TM4 of the aminergic histamine H1 receptor crystal
structure [64] is constricted, directing W1584.56x57
(an important residue for H1R ligand binding based on
mutation studies [65]) towards the aromatic ligand-binding
pocket (Figure 4C). The aminergic muscarinic acetylcholine
M2 and M3 receptor crystal structures [66,67] are not con-
stricted in TM4, and the structurally equivalent position of
the conserved tryptophan is 4.57. This again lines the
ligand-binding site and makes hydrophobic/aromatic con-
tacts with the co-crystallized ligand, in accordance with
mutation studies of W4004.57 in M2 [68] (Figure 4D). Fur-
thermore, combined mutagenesis and protein-ligand model-
ing studies to explain ligand selectivity for histamine H3and
H4 receptors [69] and H4R species variants [70] indicate that
the residues at position 4.57 (Y1674.57 in H3R and N147
4.57
in H4R) are directed towards the ligand-binding pocket. This
suggests that the TM4 of H3R and H4R are undistorted,
making the constriction unique for the H1R subtype.
constriction within the class, as seen in the GPCRDB alignments [15]. Adenosine receptor A2AR has two bulges in TM5 (D) giving a double offset, for example, 5.39 versus
5x41. Spheres represent the alpha carbon of each residue. Receptors; 5-HT2B (PDB: 4IB4), A2AR (PDB: 4EIY), b1-adrenoceptor (PDB: 4AMJ), b2-adrenoceptor (PDB: 2RH1),
CRF1 (PDB: 4K5Y), H1 (PDB: 3RZE), P2Y12 (PDB: 4NTJ), S1P1 (PDB: 3V2Y), SMO (PDB: 4JKV), and mGlu1 (PDB: 4OR2).
L2.53
L2.64x63
G2.61x60
P2.58
T2.56
D2.63
W6.48W6.48
Y6.51
F6.51
(A) (B)
I2.55
F2.53
V2.54
W2.60
P2.59x58
G2.54
V2.57x56
L2.55
L2.56x551
W4.56x57
L4.55
V4.57x58
I4.58x59
W6.48
Y6.51
W4.57
A4.58
P4.59
L4.56
I4.55
W6.48
Y6.51
(C) (D)
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Figure 4. TM bulges and constrictions orient different residue numbers in the ligand binding site in GPCR crystal structures. Comparison of the T2.56XP2.58 stabilized region
(orange) in TM2 of the CXCR4 chemokine receptor that orients W2.60 and D2.63 into the 1T1t binding site [56] (A), and the alpha-bulge in TM2 of the turkey b1-adrenoceptor that
orients G2.61x60 and L2.64x63 into the carvedilol binding site [62] (B). Comparison of the constricted region (orange) in TM4 of the histamine H1 receptor [64] that orients W
4.56x57
into the doxepin binding site (C), and TM4 of the muscarinic acetylcholine M2 receptor [66] that orients W
4.57 into the 3-quinuclidinyl-benzilate binding site (D). Ligand carbon
atoms are colored magenta. Residues W6.48 and Y/F6.51 in TM6 are shown as reference (note that TM6 in panels A–B is rotated 90˚ relative to TM6 in panels C–D).
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Numbering made easy – residue-numbering web tools
at GPCRDB
GPCRDB has been a major community resource for more
than 20 years [15,71–73]. It contains reference data includ-
ing the largest available collection of receptor mutants,
crystal structures, 3D structure models in the inactive
and active states, and sequence alignments for all species
in UniProt. Recently, GPCRDB was equipped with a new
suite of interactive web browser tools and diagrams; these
include phylogenetic trees, sequence motif search (e.g., for a
binding site), and receptor sequence plots (snake and helix
box plots). Notably, for all of the above, correct alignment of
residues in sequence and/or structure is crucial.
For pharmacologists, chemists, structural biologists,
and others to use generic residue numbers, a more conve-
nient way is needed than the manual generation of se-
quence alignments and assignment of residue numbers.
Consequently, GPCRDB provides reference alignments
and a series of residue-numbering tools. The sequence
alignments are based on the available crystal structures
and are gapped to account for bulges and constrictions
(Figure 5A). GPCRDB supports alignments of all classes
displaying both the sequence-based Ballesteros-Weinstein
(A), Wootten (B), Pin (C), and Wang (F) numbering, as well
as structure-based GPCRDB residue numbers. The align-
ments are followed by a consensus sequence and statistics
on residue/property conservation, and can be downloaded
for further analysis. A predefined set in the receptor selec-
tion allows alignment or lookup (below) of only the crys-
tallized receptors.
Lookup tables show side-by-side listing of receptor-spe-
cific and generic residue numbers (Figure 5B). The tables
can list multiple receptors, such as subtypes or species
orthologs, to facilitate the inference of for example muta-
genesis data or ligand interactions observed in crystal
structure complexes. GPCR structures can be browsed or
uploaded in Protein Data Bank (PDB) format to assign up
to two generic numbering schemes to the TM residues
(Figure 5C). The numbers are stored in the PDB file by
replacing the B-factor of the C-alpha and carbonyl carbons
and scripts are presented for visualization using PyMOL,
Maestro, or MOE (Molecular Operating Environment).
Finally, to allow compatibility and reinterpretation of
published literature, the Utopia PDF reader [74] can be
downloaded to annotate receptor residues with informa-
tion from GPCRDB. A guide to generic GPCR residue
numbering is presented in Box 1.
Potential exceptions and future directions
The sequence- and structure-based numbering systems
share some limitations. Generic residues can only be
assigned to receptor regions with a conserved structural
fold, in other words the 7TM domain, whereas the termini
and loops can only be compared, in the best case, within
receptor subfamilies. Both systems also depend on se-
quence homology to produce sequence alignments, al-
though this dependency decreases for the GPCRDB
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Structure-based alignment
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Structure numbering
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Figure 5. GPCRDB residue numbering tools. GPCRDB offers a suite of residue
numbering tools. A) Sequence alignments are gapped to account for bulges and
constrictions and list both the structure-based (GPCRDB) and sequence-based
residue numbers, for each class. The example, obtained from the structure browser
tool, shows the TM2 alignment for two crystallized class A–C receptors and one
class F GPCR. B) Lookup tables show generic and receptor-specific residue
numbers and can be used to compare the equivalent receptor residues. The
example covers TM1 for the class A receptors included in the case stories. C)
Structures can be browsed or uploaded in PDB format to assign up to two generic
numbering schemes to the transmembrane residues. The example shows the
carazolol binding site of the b2-adrenoceptor (PDB: 2RH1).
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numbering as new crystal structure templates become
available. In fact, there are seven alignments – one for
each helix. Most receptors and helices have a sufficiently
high overall sequence similarity, and the bulk of the others
can be anchored on highly conserved residue positions (e.g.,
the X.50 references). The few remaining are mostly orphan
receptors with atypical sequences [75].
Upcoming crystal structures are expected to reveal
additional offsets of the sequence-based numbering, while
improving the structure-based system. The flip-side of the
coin is that this requires the GPCRDB numbers to be
updated for the given subset of receptors and offset residue
positions. The GPCRDB numbering scheme has been
designed so that the numbers are adjusted only when a
newly determined GPCR structure reveals a new bulge or
constriction that has not been predicted by homology. It
should be pointed out that all abundant offsets, affecting
many receptors, have most likely already been covered.
Firstly, all bulges (Figure 3A–I) have a proline residue 3–5
positions downstream, and in the largest class (A) there are
no more highly conserved proline residues in the 7TM that
allow additional frequent bulges. Secondly, most other
bulges and constrictions have so far only been observed
in a single crystal structure and have a low expected
frequency, indicating that future adjustments will be lim-
ited to small receptor subfamilies or a subset of their
members. Consequently, determination of structures cov-
ering novel receptor families will be the most valuable.
Conformational plasticity and flexibility are intrinsic
features of individual receptors that have to be
accounted for in any analysis and generalization of
structural information for GPCRs. So far, generic struc-
ture-based numbering has shown good tolerance to con-
formational changes in 7TM region. Thus, our analysis
shows that the bulges and constrictions do not change
between multiple crystal structures of the same GPCR,
when available, even though these structures were de-
termined using different complexes, resolutions, stabili-
zation constructs, or crystal packing forms. Even when
relatively large conformational changes between differ-
ent activation states are considered, the corresponding
helical distortions do not involve formation of a full
bulge/constriction. This does not preclude a possibility
of such changes being found in some of the newly solved
GPCR structures in the future – in this case careful
analysis should be applied to understand the mechanism
and exclude potential artifacts.
Concluding remarks
The first crystal structures of the class B, C, and F GPCRs
have opened up the field for receptor function studies and
drug design. In addition, cross-class sequence alignments
can now be constructed, enabling us to uncover the com-
mon cogs and cranks within the 7TM machinery. We have
described the schemes for generic numbering of such resi-
due hotspots for chemical structure-activity relationships,
pharmacological effects of receptor mutants, and structur-
al mechanisms. Furthermore, the multiplicity of struc-
tures has uncovered helix bulges and constrictions,
making it clear that the correct mapping of equivalent
residues requires the gapping of sequence alignments
based on crystallographic evidence. Herein, GPCRDB pre-
sents such reference structure-based alignments and resi-
due numbers. It is recommended that a combination of
sequence-based and structure-based GPCRDB numbers is
used, for example 2.58x57, unless the comparison only
includes crystallized receptors.
Acceptance by the GPCR community will initially be
determined by simplicity – in other words counting num-
bers within the specific sequence (alignment) as compared
to looking it up in the GPCRDB alignments or tables. In the
longer term, it is more crucial how many offsets accumu-
late in the sequence-based numbering and how many can
be accepted while still preserving the utility of the system
such that the same number actually refers to the equiva-
lent residues across different GPCRs. The GPCRDB num-
bering system has been fully endorsed by the International
Union of Basic and Clinical Pharmacology Committee on
Receptor Nomenclature and Drug Classification (NC-
IUPHAR). NC-IUPHAR, together with its database Guide-
ToPharmacology [76], will be working closely with
GPCRDB to encourage acceptance of this system by the
wider GPCR community.
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